Trial Profile

Double-Blind, Single and Multiple Dose Study to Determine Pharmacodynamic Markers, Pharmacokinetic Parameters, and Safety of ALTO-203 in Patients With Major Depressive Disorder

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Mar 2025 Status changed from not yet recruiting to active, no longer recruiting.
20 Mar 2025 According to an Alto Neuroscience media release, company on track to report topline data in the second quarter of 2025.
11 Dec 2024 According to an Alto Neuroscience Inc media release, Company announced presentation of this trial at the 63rd annual meeting of the American College of Neuropsychopharmacology (ACNP), in Phoenix, Arizona, held December 8-11, 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com